Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Sponsor
Peking Union Medical College
Study ID
NCT07109765
Status
Recruiting
Apply to this trial

Conditions

  • Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — DRUG
    secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection

Study Details

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Key Dates

Start date
Jun 1, 2025
Status verified
Jul 2025
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) [ Time Frame: From enrollment to the end of treatment at Week 12 ]

Related Studies